{"entity":{"id":"kcnd2","kind":"target","name":"KCND2","aka":["potassium voltage-gated channel subfamily D member 2","A-type voltage-gated potassium channel KCND2","Kv4.2","RK5","KIAA1044"],"tldr":"KCND2 (A-type voltage-gated potassium channel KCND2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","summary":"Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain. Mediates the major part of the dendritic A-type current I(SA) in brain neurons. This current is activated at membrane potentials that are below the threshold for action potentials.\n\nOpen Targets scores its association with cancer at 0.52 (direct and indirect evidence; datatypes literature 0.74, genetic association 0.28, clinical 0.76).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:6238","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6238"},{"label":"UniProt Q9NZV8","url":"https://www.uniprot.org/uniprotkb/Q9NZV8/entry"},{"label":"NCBI Gene 3751","url":"https://www.ncbi.nlm.nih.gov/gene/3751"},{"label":"Ensembl ENSG00000184408","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000184408"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.76. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"KCND2","role":["drug-target"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:6238","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6238","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q9NZV8","url":"https://www.uniprot.org/uniprotkb/Q9NZV8/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000184408","url":"https://platform.opentargets.org/target/ENSG00000184408/associations","note":"association with cancer (MONDO_0004992) 0.52;  (GraphQL API, CC0)"}],"distribution":"one-type","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA KCND2: RNA tissue enriched (brain 32 nTPM); high antibody staining in 1 normal tissue. Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 1 specific cancer type at or above 0.5 (Lambert-Eaton myasthenic syndrome). (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas KCND2 tissue","url":"https://www.proteinatlas.org/ENSG00000184408-KCND2/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000184408 associations","url":"https://platform.opentargets.org/target/ENSG00000184408/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:6238","ensembl":"ENSG00000184408","uniprot":"Q9NZV8","entrez":"3751","firstDescribed":1998,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Kong et al, Am. J. Physiol, 1998, \"Isolation and characterization of the human gene encoding Ito: further diversity by alternative mRNA splicing\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/9843794/","biology":"Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain. Mediates the major part of the dendritic A-type current I(SA) in brain neurons. This current is activated at membrane potentials that are below the threshold for action potentials. It regulates neuronal excitability, prolongs the latency before the first spike in a series of action potentials, regulates the frequency of repetitive action potential firing, shortens the duration of action potentials and regulates the back-propagation of action potentials from the neuronal cell body to the dendrites. Contributes to the regulation of the circadian rhythm of action potential firing in suprachiasmatic nucleus neurons, which regulates the circadian rhythm of locomotor activity. Functions downstream of the metabotropic glutamate receptor GRM5 and plays a role in neuronal excitability and in nociception mediated by activation of GRM5. Location: Cell membrane; Cell projection, dendrite; Synapse; Perikaryon (UniProt). Locus 7q31.31 (HGNC).","whereFound":[],"targetClass":"other","prevalence":[]},"route":"/targets/kcnd2/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}]}}